Clinical outcomes associated with conversion to tacrolimus-based immunosuppression in pediatric cardiac transplantation.
Walker
R E
RE
Division of Cardiology, University of Toronto, Hospital for Sick Children, Ontario, Canada.
McCrindle
B W
BW
Coles
J G
JG
West
L J
LJ
D000293:Adolescent; D001379:Azathioprine / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control; D016027:Heart Transplantation / Q000276:immunology* / Q000473:pathology / Q000502:physiology; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007223:Infant; D008232:Lymphoproliferative Disorders / Q000139:chemically induced; D008297:Male; D008499:Medical Records; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D001379:Azathioprine; D011241:Prednisone; D016559:Tacrolimus